APA

Lim J., Samuelsen C., Golembesky A., Shrestha S., Wang L. & Griebsch I. (20190909). Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. : Future oncology (London, England).

Chicago

Lim Jonathan, Samuelsen Carl, Golembesky Amanda, Shrestha Sulena, Wang Li and Griebsch Ingolf. 20190909. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. : Future oncology (London, England).

Harvard

Lim J., Samuelsen C., Golembesky A., Shrestha S., Wang L. and Griebsch I. (20190909). Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. : Future oncology (London, England).

MLA

Lim Jonathan, Samuelsen Carl, Golembesky Amanda, Shrestha Sulena, Wang Li and Griebsch Ingolf. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA. : Future oncology (London, England). 20190909.